Stonepine Capital Management LLC

-

Assets, Funds, Holdings

Home | Sign Up | Log In
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
Stonepine Capital Management LLC
CRD #139891
SEC #801-136874
CIK #0001370042, 0001440771
AUM 181.0 M (2026-06-26)
Employees 4 (75% Investors, 0% Brokers)
Phone541-647-5673
Address2900 NW Clearwater Drive
Bend, OR 97703
Source [IAPD] [EDGAR] [Website]
Total AUM ($M)
3502802101407002010201520212027
Sector Form 13F Holdings Value ($M)
Verastem Inc 17.5
R&R Acquisition VI Inc 17.0
Oxygen Biotherapeutics Inc 15.6
Evolus Inc 9.0
Camp4 Therapeutics Corp 6.1
Nektar Therapeutics 6.1
Kempharm Inc 4.5
Access Pharmaceuticals Inc 3.8
Corbus Pharmaceuticals Holdings Inc 3.6
Establishment Labs Holdings Inc 3.2
View All
Holdings by Sector ($M)
3502802101407002014201820222027
Type Form D Funds Date Sold AUM
HF Metolius Capital LP [2017-03-30] 7.9 M 2.6 M
Filed 2018-12-06 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $500,000 · Remaining Indefinite · Duration More than one year · Finder's Fee $18,645 · Net Assets Decline to Disclose
HF Tumalo Capital LP [2017-03-30] 7.6 M 2.5 M
Filed 2018-12-06 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $500,000 · Remaining Indefinite · Duration More than one year · Finder's Fee $23,449 · Net Assets Decline to Disclose
HF Stonepine Capital LP 2015-03-24 181.0 M
AUM Breakdown Accounts AUM ($M)
By Client Type
(a) Individuals (other than high net worth individuals) 0 0.0
(b) Individuals (high net worth individuals) 0 0.0
(c) Banking or thrift institutions 0 0.0
(d) Investment companies 0 0.0
(e) Business development companies 0 0.0
(f) Pooled investment vehicles 1 181.0
(g) Pension and profit sharing plans 0 0.0
(h) Charitable organizations 0 0.0
(i) State or municipal government entities 0 0.0
(j) Other investment advisers 0 0.0
(k) Insurance companies 0 0.0
(l) Sovereign wealth funds and foreign official institutions 0 0.0
(m) Corporations or other businesses not listed above 0 0.0
(n) Other 0 0.0
Total 1 181.0
By Discretionary
Discretionary 1 181.0
Non-Discretionary 0 0.0
Total 1 181.0
By Non-United States Persons
Non-United States Persons 0.0
United States Persons 181.0
Total 1 181.0
Form D Directors Role # Filings # Firms 2011 - 2026
Timothy Lynch Executive Officer 7 2
Matt Carroll Executive Officer 4 2
Jon Plexico Executive Officer 3 2
Stonepine Capital Management LLC Executive Officer 3 2
Jeff Nunnenkamp Executive Officer 3 2
EDGAR Form CIK 2011 - 2026
3 [0001370042]
4 [0001370042]
SC 13D [0001370042]
SC 13G [0001370042]
13F-HR [0001440771]
3 [0001440771]
4 [0001440771]
SC 13G [0001440771]
Form 13D/13G Filer Form 13D/13G Subject Filed
Stonepine Capital Management LLC Pasithea Therapeutics Corp [2026-06-23]
Stonepine Capital Management LLC Azitra Inc [2026-06-22]
Stonepine Capital Management LLC Eloxx Pharmaceuticals Inc [2026-06-16]
Stonepine Capital Management LLC Sintx Technologies Inc [2026-06-09]
Stonepine Capital Management LLC Cellectar Biosciences Inc [2026-05-11]
Stonepine Capital Management LLC Curis Inc [2026-03-27]
Stonepine Capital Management LLC In8Bio Inc [2025-12-22]
Stonepine Capital Management LLC Quoin Pharmaceuticals Ltd [2025-12-16]
Stonepine Capital Management LLC CNS Pharmaceuticals Inc [2025-11-04]
Stonepine Capital Management LLC Verastem Inc [2025-08-06]
View All
Firm Profile (Form ADV)
ServesInstitutional
Fund TypesHedge Fund
LEI213800AIP1E4A547KD30
Form 3/4/5 Subject 2011 - 2026
Stonepine Capital Management LLC
Quoin Pharmaceuticals Ltd
Chiasma Inc
Stonepine Capital LP
Novelion Therapeutics Inc
Lpath Inc
Societal CDMO Inc
Lynch Timothy P
Viveve Medical Inc
Plexico Jon M
Insider Transaction (Form 3/4/5) Date Action Shares Price Value ($)
Chiasma Inc CHMA
Common Stock
2021-08-05 Disposed to issuer 6,770,000
Novelion Therapeutics Inc NVLNF
Common Stock
2019-12-12 Buy 1,000 $0.70 700
Novelion Therapeutics Inc NVLNF
Common Stock
2019-12-11 Buy 40 $0.69 28
Novelion Therapeutics Inc NVLNF
Common Stock
2019-12-10 Buy 5,202 $0.69 3,589
Novelion Therapeutics Inc NVLNF
Common Stock
2019-12-09 Buy 4,500 $0.70 3,150
Novelion Therapeutics Inc NVLNF
Common Stock
2019-12-06 Buy 40 $0.70 28
Novelion Therapeutics Inc NVLNF
Common Stock
2019-12-05 Buy 5,160 $0.70 3,612
Novelion Therapeutics Inc NVLNF
Common Stock
2019-11-22 Buy 89,845 $0.75 67,384
Novelion Therapeutics Inc NVLNF
Common Stock
2019-10-11 Buy 100,000 $0.65 65,000
Lpath Inc APEN
Warrant · derivative
2019-08-12 Other 1
Lpath Inc APEN
6.0% Convertible Debenture due 2024 · derivative
2019-08-12 Buy $2,775,000.00
Lpath Inc APEN
Common Stock
2019-08-12 Other 1,000,000
Lpath Inc APEN
Common Stock
2018-12-27 Sell 250,000 $3.00 750,000
Lpath Inc APEN
Common Stock
2018-12-26 Sell 500,000 $3.00 1,500,000
Lpath Inc APEN
Common Stock
2018-11-21 Buy 3,230 $3.61 11,660
Lpath Inc APEN
Common Stock
2018-11-19 Buy 54,200 $3.40 184,280
Lpath Inc APEN
Common Stock
2018-11-02 Buy 300,000 $5.00 1,500,000
Lpath Inc APEN
Common Stock
2018-01-03 Buy 6,339 $5.78 36,639
Lpath Inc APEN
Common Stock
2018-01-02 Buy 11,343 $5.73 64,995
Lpath Inc APEN
Common Stock
2017-12-29 Buy 5,163 $5.56 28,706
showing 20 of 43 most recent transactions
Comparable Firms State AUM
X Cubed Capital Management LLC
MN 184.0 M
Open Door Investment Management Ltd
CA 183.4 M
Smith Asset Management Group LP
TX 182.2 M
Emmett Investment Management LP
NY 181.6 M
Alpine Woods Capital Investors LLC
NY 180.6 M
2E Capital Partners LP
NY 180.0 M
Daventry Group LP
NY 179.9 M
Arc24 Management LP
NY 179.7 M
Gallo Partners LP
179.0 M
Candelo Capital Management LP
NY 178.1 M
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com